Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06710080
PHASE3

Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia

Sponsor: Ottawa Heart Institute Research Corporation

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is: What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP. Participants wil: * take Vacscepa or a placebo twice a day for 6 months * Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests

Official title: Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia (TIN_CAP): a Multi-centre, Prospective, Randomized Control Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

168

Start Date

2024-12-15

Completion Date

2027-06

Last Updated

2024-12-05

Healthy Volunteers

No

Interventions

DRUG

Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]

Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.

DRUG

Placebo

Placebo twice daily

Locations (1)

University of Ottawa Heart Institute

Ottawa, Ontario, Canada